HBM Holdings (HBM Holdings) Interest Coverage : 12.23 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is HBM Holdings Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. HBM Holdings's Operating Income for the six months ended in Dec. 2023 was $18.65 Mil. HBM Holdings's Interest Expense for the six months ended in Dec. 2023 was $-1.53 Mil. HBM Holdings's interest coverage for the quarter that ended in Dec. 2023 was 12.23. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for HBM Holdings's Interest Coverage or its related term are showing as below:

HBMHF' s Interest Coverage Range Over the Past 10 Years
Min: 5.85 Med: 5.85 Max: 5.85
Current: 5.85

HBMHF's Interest Coverage is ranked worse than
81.82% of 341 companies
in the Biotechnology industry
Industry Median: 142.97 vs HBMHF: 5.85

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

HBM Holdings Interest Coverage Historical Data

The historical data trend for HBM Holdings's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

HBM Holdings Interest Coverage Chart

HBM Holdings Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Coverage

Get a 7-Day Free Trial

5.85

HBM Holdings Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Interest Coverage	Get a 7-Day Free Trial						-	-	-	1.71	12.23

Competitive Comparison of HBM Holdings's Interest Coverage

For the Biotechnology subindustry, HBM Holdings's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

HBM Holdings's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, HBM Holdings's Interest Coverage distribution charts can be found below:

* The bar in red indicates where HBM Holdings's Interest Coverage falls into.

HBM Holdings Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage

-1

Operating Income

Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt ⁽¹⁾.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

HBM Holdings's Interest Coverage for the fiscal year that ended in Dec. 2023 is calculated as

Here, for the fiscal year that ended in Dec. 2023, HBM Holdings's Interest Expense was $-3.87 Mil. Its Operating Income was $22.67 Mil. And its Long-Term Debt & Capital Lease Obligation was $28.58 Mil.

Interest Coverage	=	-1	*	Operating Income (A: Dec. 2023 )	/	Interest Expense (A: Dec. 2023 )
	=	-1	*	22.667	/	-3.872
	=	5.85

HBM Holdings's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Here, for the six months ended in Dec. 2023, HBM Holdings's Interest Expense was $-1.53 Mil. Its Operating Income was $18.65 Mil. And its Long-Term Debt & Capital Lease Obligation was $28.58 Mil.

Interest Coverage	=	-1	*	Operating Income (Q: Dec. 2023 )	/	Interest Expense (Q: Dec. 2023 )
	=	-1	*	18.648	/	-1.525
	=	12.23

The higher the ratio, the stronger the company's Financial Strength is.

HBM Holdings (OTCPK:HBMHF) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .

HBM Holdings Interest Coverage Related Terms

Thank you for viewing the detailed overview of HBM Holdings's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.

HBM Holdings (HBM Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » HBM Holdings Ltd (OTCPK:HBMHF) » Definitions » Interest Coverage

Comparable Companies

Traded in Other Exchanges

02142:Hong Kong

Address

420 Fenglin Road, 12th Floor, Tower A, Fenglin International Plaza Phase II, Xuhui District, Shanghai, CHN, 200032

Website

https://www.harbourbiomed.com

HBM Holdings Ltd is a clinical-stage biopharmaceutical company engaged in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. Its products under development are Batoclimab, for the treatment of a wide spectrum of autoimmune diseases; Tanfanercept, for the treatment of moderate-to-severe dry eye disease (DED); HBM4003; HBM9378, to prevent and treat COVID-19, the pandemic respiratory disease caused by the SARS-CoV-2 virus; HBM7008; and others. Its geographical segments are Mainland China, United States, Europe, and others. Majority of revenue is generated from Europe.

HBM Holdings (HBM Holdings) Headlines

From GuruFocus

Harbour BioMed Announces Positive Profit Alert

By PRNewswire • 01-19-2024